Literature DB >> 12227495

Malignant potential of the reticular form of oral lichen planus over a 25-year observation period in 55 patients from Slovenia.

Matjaz Rode1, Mirela Kogoj-Rode.   

Abstract

A retrospective evaluation of the reticular form of oral lichen planus was made on the basis of clinical and histopathological observations in 55 patients. Patients were re-examined once every six months over a 25-year period. Biopsies were taken from all lesions. No cases of complete remission and no cases of malignant transformation were recorded. Our findings suggest that the reticular form of oral lichen planus is not a precancerous lesion.

Entities:  

Mesh:

Year:  2002        PMID: 12227495

Source DB:  PubMed          Journal:  J Oral Sci        ISSN: 1343-4934            Impact factor:   1.556


  5 in total

1.  Serum level of matrix metalloproteinase-3 in patients with oral lichen planus.

Authors:  M Farzin; M Mardani; J Ghabanchi; M J Fattahi; M Rezaee; S T Heydari; A Andisheh Tadbir
Journal:  Iran Red Crescent Med J       Date:  2012-01-01       Impact factor: 0.611

2.  [Assessment of severity of oral lichen planus using a new clinical index].

Authors:  G Bethke; P A Reichart
Journal:  Mund Kiefer Gesichtschir       Date:  2005-05

3.  Correlation between tissue expression of microRNA-137 and CD8 in oral lichen planus.

Authors:  Sana Maher Hasan Aghbari; Abdelrahman Ibrahim Abushouk; Olfat Gamil Shakir; Shaimaa Omar Zayed; Attia Attia
Journal:  Clin Oral Investig       Date:  2017-10-15       Impact factor: 3.573

4.  Interleukin-6 released by oral lichen planus myofibroblasts promotes angiogenesis.

Authors:  Xiao-Heng Xu; Yang Liu; Lu Feng; Yin-Shen Yang; Shu-Guang Liu; Wei Guo; Hui-Xi Zhou; Zhi-Qiang Li; Lin Zhang; Wen-Xia Meng
Journal:  Exp Ther Med       Date:  2021-01-27       Impact factor: 2.447

5.  Salivary levels of tumor necrosis factor-alpha in oral lichen planus.

Authors:  Sonja Pezelj-Ribaric; Ivana Brekalo Prso; Maja Abram; Irena Glazar; Gordana Brumini; Marica Simunovic-Soskic
Journal:  Mediators Inflamm       Date:  2004-04       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.